IL6 and metabolic syndrome: Nevertheless, rs1800629 has been previously reported to modulate the expression of key components within the inflammatory signaling cascade, which could influence the production of pro-inflammatory cytokines such as IL-6, TNF-α, IFN-γ, particularly in patients with metabolic syndrome (25, 26).